{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:17:56Z","timestamp":1780661876613,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is characterized by the accumulation of malignant and immature white blood cells which spread to the peripheral blood and other tissues\/organs. Despite the fact that current tyrosine kinase inhibitors (TKIs) are capable of achieving the complete remission by reducing the tumor burden, severe adverse effects often occur in CML patients treated with TKIs. The differentiation therapy exhibits therapeutic potential to improve cure rates in leukemia, as evidenced by the striking success of all-trans-retinoic acid in acute promyelocytic leukemia treatment. However, there is still a lack of efficient differentiation therapy strategy in CML. Here we showed that <jats:italic>MPL<\/jats:italic>, which encodes the thrombopoietin receptor driving the development of hematopoietic stem\/progenitor cells, decreased along with the progression of CML. We first elucidated that MPL signaling blockade impeded the megakaryocytic differentiation and contributed to the progression of CML. While allogeneic human umbilical cord-derived mesenchymal stem cells (UC-MSCs) treatment efficiently promoted megakaryocytic lineage differentiation of CML cells through restoring the <jats:italic>MPL<\/jats:italic> expression and activating MPL signaling. UC-MSCs in combination with eltrombopag, a non-peptide MPL agonist, further activated JAK\/STAT and MAPK signaling pathways through MPL and exerted a synergetic effect on enhancing CML cell differentiation. The established combinational treatment not only markedly reduced the CML burden but also significantly eliminated CML cells in a xenograft CML model. We provided a new molecular insight of thrombopoietin (TPO) and MPL signaling in MSCs-mediated megakaryocytic differentiation of CML cells. Furthermore, a novel anti-CML treatment regimen that uses the combination of UC-MSCs and eltrombopag shows therapeutic potential to overcome the differentiation blockade in CML.<\/jats:p>","DOI":"10.1038\/s41419-021-03499-w","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T15:16:12Z","timestamp":1614179772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Shiman","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luchen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-784X","authenticated-orcid":false,"given":"Pingping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"3499_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake, T. L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129, 1595\u20131606 (2017).","journal-title":"Blood"},{"key":"3499_CR2","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.3390\/ijms20246141","volume":"20","author":"L Bavaro","year":"2019","unstructured":"Bavaro, L., Martelli, M., Cavo, M. & Soverini, S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: An update. Int. J. Mol. Sci. 20, 6141 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"3499_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am. J. Hematol. 93, 442\u2013459 (2018).","journal-title":"Am. J. Hematol."},{"key":"3499_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti, G., Castagnetti, F., Gugliotta, G. & Baccarani, M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat. Rev. Clin. Oncol. 14, 141\u2013154 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3499_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini, S., Mancini, M., Bavaro, L., Cavo, M. & Martinelli, G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol. Cancer 17, 49 (2018).","journal-title":"Mol. Cancer"},{"key":"3499_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"3499_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/cancers3022402","volume":"3","author":"E Gocek","year":"2011","unstructured":"Gocek, E. & Marcinkowska, E. Differentiation therapy of acute myeloid leukemia. Cancers 3, 2402\u20132420 (2011).","journal-title":"Cancers"},{"key":"3499_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.5","volume":"3","author":"W Zhao","year":"2013","unstructured":"Zhao, W. et al. MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation. Blood Cancer J. 3, e107 (2013).","journal-title":"Blood Cancer J."},{"key":"3499_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2016.11.005","volume":"133","author":"HM Ahmad","year":"2017","unstructured":"Ahmad, H. M., Muiwo, P., Muthuswami, R. & Bhattacharya, A. FosB regulates expression of miR-22 during PMA induced differentiation of K562 cells to megakaryocytes. Biochimie 133, 1\u20136 (2017).","journal-title":"Biochimie"},{"key":"3499_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.tiv.2009.06.027","volume":"23","author":"YC Huang","year":"2009","unstructured":"Huang, Y. C., Chao, D. K., Clifford Chao, K. S. & Chen, Y. J. Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. Toxicol. In Vitro 23, 979\u2013985 (2009).","journal-title":"Toxicol. In Vitro"},{"key":"3499_CR11","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2014-03-559815","volume":"124","author":"R Besancenot","year":"2014","unstructured":"Besancenot, R et al. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood 124, 2104\u20132115 (2014).","journal-title":"Blood"},{"key":"3499_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029014","volume":"6","author":"HL Huang","year":"2011","unstructured":"Huang, H. L. et al. Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. PLoS ONE 6, e29014 (2011).","journal-title":"PLoS ONE"},{"key":"3499_CR13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1172\/JCI79196","volume":"126","author":"B Zhang","year":"2016","unstructured":"Zhang, B et al. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. J. Clin. Invest. 126, 975\u2013991 (2016).","journal-title":"J. Clin. Invest."},{"key":"3499_CR14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","volume":"32","author":"S Xu","year":"2018","unstructured":"Xu, S., De Veirman, K., De Becker, A., Vanderkerken, K. & Van Riet, I. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia 32, 1500\u20131514 (2018).","journal-title":"Leukemia"},{"key":"3499_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00441-018-2961-4","volume":"375","author":"RA Poltavtseva","year":"2018","unstructured":"Poltavtseva, R. A., Poltavtsev, A. V., Lutsenko, G. V. & Svirshchevskaya, E. V. Myths, reality and future of mesenchymal stem cell therapy. Cell Tissue Res. 375, 563\u2013574 (2018).","journal-title":"Cell Tissue Res."},{"key":"3499_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41375-018-0373-9","volume":"33","author":"MW Lee","year":"2019","unstructured":"Lee, M. W et al. Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges. Leukemia 33, 597\u2013611 (2019).","journal-title":"Leukemia"},{"key":"3499_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15283\/ijsc.2009.2.1.59","volume":"2","author":"P Chae Woon","year":"2009","unstructured":"Chae Woon, P. et al. Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int. J. Stem Cells 2, 59\u201368 (2009).","journal-title":"Int. J. Stem Cells"},{"key":"3499_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood-2018-04-842641","volume":"133","author":"K Tozawa","year":"2019","unstructured":"Tozawa, K et al. Megakaryocytes and platelets from a novel human adipose tissue\u2013derived mesenchymal stem cell line. Blood 133, 633\u2013643 (2019).","journal-title":"Blood"},{"key":"3499_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.15034","volume":"180","author":"Y He","year":"2018","unstructured":"He, Y et al. Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3\/NF-\u03baB\/SMAD pathway in patients with immune thrombocytopenia. Br. J. Haematol. 180, 395\u2013411 (2018).","journal-title":"Br. J. Haematol."},{"key":"3499_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"3499_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"3499_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).","journal-title":"BMC Bioinformatics"},{"key":"3499_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40261-018-0670-0","volume":"38","author":"T Hamada","year":"2018","unstructured":"Hamada, T. et al. Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia. Clin. Drug Investig. 38, 813\u2013818 (2018).","journal-title":"Clin. Drug Investig."},{"key":"3499_CR24","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 28, 2529\u20132537 (2010).","journal-title":"J. Clin. Oncol."},{"key":"3499_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2008.07261.x","volume":"142","author":"A Kohlmann","year":"2008","unstructured":"Kohlmann, A. et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br. J. Haematol. 142, 802\u2013807 (2008).","journal-title":"Br. J. Haematol."},{"key":"3499_CR26","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.4049\/jimmunol.1900692","volume":"203","author":"S Biswas","year":"2019","unstructured":"Biswas, S et al. Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer. J. Immunol. 203, 3447\u20133460 (2019).","journal-title":"J. Immunol."},{"key":"3499_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12185-008-0030-6","volume":"87","author":"R Liang","year":"2008","unstructured":"Liang, R. et al. Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60\/VCR. Int. J. Hematol. 87, 152\u2013166 (2008).","journal-title":"Int. J. Hematol."},{"key":"3499_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.4161\/auto.5.8.9889","volume":"5","author":"P Colosetti","year":"2009","unstructured":"Colosetti, P. et al. Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. Autophagy 5, 1092\u20131098 (2009).","journal-title":"Autophagy"},{"key":"3499_CR29","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","volume":"133","author":"LJ Alvarado","year":"2019","unstructured":"Alvarado, L. J. et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-gamma. Blood 133, 2043\u20132055 (2019).","journal-title":"Blood"},{"key":"3499_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo, J. V. & Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441\u2013453 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"3499_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand, M. et al. Chronic myeloid leukemia stem cells. Leukemia 33, 1543\u20131556 (2019).","journal-title":"Leukemia"},{"key":"3499_CR32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost, S. et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 525, 380\u2013383 (2015).","journal-title":"Nature"},{"key":"3499_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123\u20131132 (2015).","journal-title":"Leukemia"},{"key":"3499_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.12772","volume":"165","author":"IS Hitchcock","year":"2014","unstructured":"Hitchcock, I. S. & Kaushansky, K. Thrombopoietin from beginning to end. Br. J. Haematol. 165, 259\u2013268 (2014).","journal-title":"Br. J. Haematol."},{"key":"3499_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fendo.2017.00234","volume":"8","author":"I Plo","year":"2017","unstructured":"Plo, I et al. Genetic alterations of the thrombopoietin\/MPL\/JAK2 axis impacting megakaryopoiesis. Front. Endocrinol. 8, 234 (2017).","journal-title":"Front. Endocrinol."},{"key":"3499_CR36","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1182\/blood-2012-03-414649","volume":"120","author":"JA Pulikkan","year":"2012","unstructured":"Pulikkan, J. A. et al. Thrombopoietin\/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K\/AKT signaling. Blood 120, 868\u2013879 (2012).","journal-title":"Blood"},{"key":"3499_CR37","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/blood-2013-12-546275","volume":"124","author":"S Nishikawa","year":"2014","unstructured":"Nishikawa, S. et al. Thrombopoietin\/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia. Blood 124, 3587\u20133596 (2014).","journal-title":"Blood"},{"key":"3499_CR38","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2016-04-711986","volume":"128","author":"PJ Rauch","year":"2016","unstructured":"Rauch, P. J et al. MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. Blood 128, 2253\u20132257 (2016).","journal-title":"Blood"},{"key":"3499_CR39","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2008.20","volume":"22","author":"YS Tang","year":"2008","unstructured":"Tang, Y. S., Zhang, Y. P. & Xu, P. hNUDC promotes the cell proliferation and differentiation in a leukemic cell line via activation of the thrombopoietin receptor (Mpl). Leukemia 22, 1018\u20131025 (2008).","journal-title":"Leukemia"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03499-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:31:15Z","timestamp":1669919475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03499-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["3499"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03499-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"23 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review and ethics boards at Nanjing Drum Tower Hospital of Nanjing University, Nanjing. All mouse procedures and experiments for this study were approved by the Institutional Animal Care and Use Committee at Nanjing University (ICAUA No is ICAUC-2007021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"208"}}